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Background: Gonadal dysgenesis (GD) is associated with increased risk of gonadal malignancy. Determining a
patient’s risk and appropriate timing of gonadectomy is challenging, but immunohistochemical markers (IHM) may
help establish the diagnosis of malignant germ cell tumors (GCT). Our objective was to identify the prevalence of
specific IHM expression in patients with GD and determine if the patterns of expression can help identify
malignancy versus pre-malignancy state. We evaluated the published literature using the Grading of Recommendation,
Assessment, Development, and Evaluation (GRADE) system to provide recommendations on the predictive role of IHM
in the detection of germ cell malignancy.
Methods: The data for this retrospective study included karyotype, gonadal location, external masculinization score, age
at time of gonadectomy or biopsy, microscopic description and diagnosis of gonadal tissue, and immunohistochemical
staining, including octamer binding transcription factor (OCT) 3/4, placental-like alkaline phosphatase (PLAP), β-catenin,
alpha-fetoprotein (AFP), and stem cell factor receptor CD117 (c-KIT). Patients with complete or partial GD who had
undergone gonadectomy or gonadal tissue biopsy were included.
Results: The study included 26 patients with GD, 3 of whom had evidence of GCT (11.5 %, gonadoblastoma,
dysgerminoma): 2 had Swyer syndrome, 1 had 46,XY partial GD. One patient with XY partial GD had gonadoblastoma-
like tissue. All 4 patients (15 %) had strong expressions of 4 tumor markers (OCT 3/4, PLAP, β-catenin, CD117), as did 5
other patients (19 %, ages 2–14 months) without GCT: 4 had XY GD, 1 had 46,XX GD. β-catenin was expressed in 96 %
of patients in a cytoplasmic pattern, CD117 in 78 %, OCT 3/4 in 55 %, PLAP in 37 %, and AFP in 1 patient (4 %). Tumor
marker expression was not specific for ruling out malignancy in patients <1 year.
Conclusions: In patients older than 1 year, expression of all three markers (OCT 3/4, PLAP, CD117) may be instrumental
in the decision-making process for gonadectomy, even in the absence of overt germ cell malignancy. Our literature
review suggests that OCT 3/4 expression is most helpful in predicting risk of malignancy. Additional criteria are needed
to stratify risk in patients younger than 1 year of age, as these markers are not reliable in that age group.
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Gonadal dysgenesis (GD), a condition with interrupted
gonadal development leading to gonadal dysfunction, is
a subset of disorders of sexual differentiation (DSD).
Dysgenetic gonads are characterized by varying degrees
of immaturity or dysfunction which can present with a
wide range of genital ambiguity. Depending on the go-
nadal morphology, GD can be classified as either complete
(CGD) or partial (PGD) [1]. CGD is characterized by a* Correspondence: mccann@bcm.edu
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creativecommons.org/publicdomain/zero/1.0/lack of testicular development, presenting as phenotypic
females with bilateral streak gonads. In contrast, PGD is
characterized by partial testicular development and often
presents with ambiguous genitalia. The gonadal histology
in PGD typically consists of hypoplastic testicular tubules
intermixed with areas of ovarian-like stroma [2]. Patients
with GD who have Y-chromosome material are at in-
creased risk for the development of type II germ cell
tumors (GCT), including dysgerminoma (DG) and semi-
noma arising from their precursor lesions gonadoblastoma
(GB) and carcinoma in situ (CIS)/intratubular germ cell
neoplasia unclassified (ITGCNU), respectively [3]. EarlyAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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GD who have a Y-chromosome component to prevent the
development of malignancy, but recommendations for
the timing of the gonadectomy remain controversial. Al-
though gonadectomy is effective in preventing gonadal
malignancy, it leads to infertility and requires a lifelong
commitment to taking hormone-replacement therapy.
Guidelines for a more conservative approach than exclu-
sively performing gonadectomy are lacking.
Determining a patient’s risk for development of gonadal
malignancy is necessary in the decision-making process
for performing a gonadectomy. Certain factors, includ-
ing the underlying etiology of the GD, location of the
gonads, degree of virilization, and certain tumor marker
expression in gonadal tissue, are known to influence the
risk of developing gonadal malignancy. The risk of de-
veloping gonadal malignancy in patients with 46, XY
complete GD (CGD; i.e., Swyer syndrome) has been re-
ported to be 15-45 %, whereas the risk is reported to be
15-40 % in patients with partial GD (PGD) who have
45,X/46,XY and other chromosomal variants [4–7].
Gonads that are located intra-abdominally are at higher
risk of developing tumors compared to those that are
located in the scrotum. Studies also have shown that a
correlation exists between the degree of virilization of
the external genitalia and the risk of developing gonadal
malignancy, with the lowest risk seen in normally viri-
lized males and the highest risk in patients with am-
biguous genitalia, reflective of the degree of testicular
function [8].
Immunohistochemical markers including octamer
binding transcription factor (OCT) 3/4, stem cell factor
receptor CD117 (C-KIT), testis-specific protein on the
Y chromosome (TSPY) gene, alpha-fetoprotein (AFP),
placental-like alkaline phosphatase (PLAP), and β-
catenin have been established as markers of germ cell
malignancy. Several studies have investigated the use of
these markers to assess for early neoplastic changes.
OCT 3/4 is a transcription factor that is essential for
the maintenance of pluripotentiality of embryonic stem
cells and primordial germ cells [9]. Abnormal regulation
of OCT 3/4 leads to inappropriate cell survival and has
been shown to be present in precursor cells of type II
GCTs. β-catenin is involved in regulating cell differenti-
ation and may interact with OCT 3/4 in the transform-
ation of GB into seminoma/DG [10]. CD 117 is the
receptor for stem cell factor (SCF), and is responsible
for proper migration of primordial germ cells during
development. It is present only in immature germ cells
and is highly expressed in early stages of germ cell devel-
opment [11]. Placental-like alkaline phosphatase (PLAP) is
a marker for primordial germ cells and is present in CIS
and GB [12]. The TSPY gene is thought to act as an onco-
gene in the context of a dysgenetic gonad, leading to thedevelopment of GB [13]. AFP is a well-known marker for
GCTs with yolk sac differentiation [14].
The objective of our study was to analyze the prema-
lignant and malignant gonadal pathology findings in pa-
tients with GD and to determine the prevalence of
specific immunohistochemical marker expressions. Our
findings prompted us to evaluate the literature using the
Grading of Recommendation, Assessment, Development,
and Evaluation (GRADE) system on risk factors that are
predictive of malignancy, as this is a major concern for
pediatric endocrinologists and urologists when they must
decide which patients require gonadectomy, and which
may benefit from a more conservative approach with re-
tention of the gonads.Methods
The protocol for this study was approved by Institutional
Review Board at Baylor College of Medicine, Houston,
Texas.Tissue collection and clinical data
Gonadectomy or gonadal biopsy samples from 26 patients
with GD were retrieved from the archives of the pathology
department at Texas Children’s Hospital, Houston, Texas.
All samples were reviewed by M.J.H., an American Board
of Pathology (Tampa, FL, USA) certified anatomic path-
ologist experienced in germ cell malignancy and gonadal
histology, in order to confirm the diagnosis and determine
if adequate tissue from the lesions was available for immu-
nohistochemical evaluation. A patient was considered to
have XY GD if there was an XY karyotype and histologic
evidence of deficient testicular development. A patient
was considered to have XX GD if there was an XX karyo-
type and histologic evidence of testicular development
and ambiguous genitalia. Patients who had complete ab-
sence of testicular tissue with a female phenotype were
considered to have CGD, whereas patients who had some
testicular tissue and ambiguous genitalia were considered
to have PGD. Additional clinical data were obtained retro-
spectively from the medical records and included the pa-
tients’ karyotype, age at time of gonadectomy or gonadal
biopsy, location of gonads, sex assignment, and the
external masculinization score (EMS). The EMS is an
objective measure of the degree of virilization of the
genitalia and takes into account individual features in-
cluding the presence or absence of scrotal fusion, loca-
tion of the urethral meatus, penile length, and the
location of each gonad [15]. The scores range from
0–12, with a score of 0 representing a phenotypic female
and a score of 12 representing a normally virilized male.
Patients with lack of detailed external phenotype de-
scriptions or insufficient gonadal tissues for staining and
review were excluded.
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Tissue sections were prepared from formalin-fixed em-
bedded paraffin tissue blocks for hematoxylin-eosin
(H&E) staining for routine microscopic examination and
for immunohistochemical staining. All routine H&E and
immunohistochemical staining were performed in an
anatomic pathology laboratory certified by the College of
American Pathologists (CAP) (Northfield, IL, USA),
using procedures certified by the CAP with appropriate
positive and negative controls and using automated
H&E (Leica Microsystems, Inc., Buffalo, IL, USA) and
immunohistochemical (Leica Bond III Automated Im-
munohistochemical and In Situ Hybridization Biosystem,
Leica Microsystems) staining systems that have undergone
inspection by the CAP. Automated immunohistochemical
staining was performed using proprietary citrate-buffered
and surfactant reagents (Novocastra Bond Epitope Re-
trieval System 1, Leica Microsystems, Inc.) and propri-
etary antibody kits (Novacastra-Leica Microsystems, Inc.)
titrated for OCT 3/4 (clone: NCL-L-OCT3/4), PLAP
(clone: NCL-L-PLAP-8A9), β-catenin (clone: NCL-L-B-
CAT), CD117 (clone: (c-kit) (clone: YR145 Rab)), and
AFP (clone: NCL-L-AFP). Appropriate positive and nega-
tive controls for each antibody were utilized. All tissue
sectioning, routine H&E staining, and immunohisto-
chemical staining were performed by histotechnologists
certified by the American Society of Clinical Pathology
(ASCP) (Chicago, IL, USA).
Microscopic examinations of the immunohistochemical
staining with each antibody were reviewed concurrently
by two examiners (MJH, BMC) in a blinded fashion. The
tissue sections from each specimen were evaluated based
upon strength of immunoreactivity (negative = 0; weak +;
strong ++), origin of tissue immunoreacting (ovarian,
testicular), and the cytologic component immunoreacting
(cytoplasmic or nuclear).
Statistical analysis
The prevalence of germ cell neoplasia was calculated for
each subgroup of GD (XY CGD, XY PGD, and XX GD).
Sensitivity and specificity for each immunohistochemical
marker were calculated with 95 % confidence intervals.
The positive predictive value for each immunohistochemical
marker was calculated using Bayes rule, given the reported
prevalence of germ cell neoplasia in GD as 15-40 %.
Evaluation of the literature
We identified a clinically relevant question to be an-
swered from the evidence for the management of pa-
tients with GD:
In patients with gonadal dysgenesis, is there a
predictive role of immunohistochemical markers in the
detection of germ cell malignancy?We searched databases for research-based articles on
pediatric patients with GD and immunohistochemical
staining. The databases included Pub Med, Cochrane
Collaboration, and Google Scholar. We included only ar-
ticles published in English and studies that included
more than five patients. Specific keywords and terms
used included: immunohistochemistry, XY gonadal dys-
genesis, germ cell tumor, GB, and DG. The GRADE sys-
tem was used to evaluate the literature and provide
recommendations [16]. The quality of the evidence was
evaluated as “very-low quality,” “low quality,” “moderate
quality,” or “high quality.” The recommendations pro-
vided were either “strong” or “weak”.
Results
The clinical data for the 26 cases included in this study
are shown in Table 1. Patient 14 had a right gonadectomy
at age 12 months and a left testicular biopsy at 33 months,
thus a total of 27 gonadal samples were reviewed in this
study. Twenty patients had XY PGD, four patients had
XX PGD, and two patients had XY CGD. The age at the
time of gonadectomy or gonadal biopsy ranged from
2 months to 18 years (median, 20 months). Three patients
(11.5 %) had evidence of GCT, two of whom had XY CGD
and one who had XY PGD. Both of the XY CGD patients
had both a GB (Fig. 1) and DG (Fig. 2), whereas the pa-
tient with XY PGD had only a GB. An additional patient
with XY PGD had tissue resembling a GB (Fig. 3) and was
classified as having in-situ neoplasia.
The immunohistochemical findings are summarized in
Table 1 according to the type of gonadal tissue that was
encountered (streak gonad, ovarian and testicular compo-
nents, testicular tissue, GB-like, GB, and DG). The three
patients with a GCT and the one patient with GB-like tis-
sue all showed strong expression of four tumor markers
(OCT 3/4, PLAP, β-catenin, and CD117). Five additional
patients (patients 10, 13, 14a, 16, and 21) who did not have
evidence of GCT on microscopy also showed strong ex-
pression of the same four markers. Four of these five add-
itional patients (age ranges, 2–12 months) had XY PGD
and one (aged 14 months) had XX PGD. The overall ex-
pression of the immunohistochemical markers from all
cases was as follows: β-catenin in 96 % of total samples,
CD117 in 78 %, OCT 3/4 in 55 %, PLAP in 37 %, and AFP
in 4 %.
The sensitivity, specificity, and positive predictive
value (given the prevalence of gonadal malignancy in
GD as reported in the literature at 15-40 %) were calcu-
lated for each immunohistochemical marker individually,
as well as the combination of OCT 3/4, PLAP, and
CD117 and are shown in Table 2. Positive staining for
all three markers (OCT 3/4, PLAP, and CD117) as well
as positive staining alone for PLAP showed the highest
sensitivity (100 %, 95 % CI 40.2-100 %), specificity (73.9 %,
Table 1 Clinical characteristics and immunohistochemical staining results







Malignancy Gonadal tissue type OCT 3/4 PLAP Β-Catenin AFP CD117
1 6 y XY PGD F 45,X[16]/46,X +mar[4],
SRY positive
Abdomen 1 No Streak - - ++C - +C
2 11 y XY PGD F 45,X/46,XY Abdomen 1 No Streak - - ++C - +C
3 12 y XY PGD F 45,X/46,XY Abdomen 1 No Streak - - ++C - -
4 16 y XY PGD F 45,X[11]/46, X,
idic (Y) (q11.21)
Abdomen 1 No Streak - - ++N - -
5 7 m XY PGD M 45, X/46, XY L- abdomen 8.5 No Streak - - ++C - -
R- scrotum
6 7 m XY PGD M 45, X/46, XY L-Scrotum 11.5 No Streak - - ++C - -
R-abdomen
7 4 m XX PGD M 46, XX Inguinal 3 No O/T +C, T & O - ++C, T & O - +C, T
++C, O
8 6 m XX PGD M 46, XX Inguinal 4 No O/T +C, T & O - ++C, T & O - +C, T
++C, O
9 2 y XX PGD M 46, XX Inguinal 5 No O/T +C, T & O - -T - -T
++C, O ++C, O
10 5 m XY PGD M 46, XX/46, XXY L-scrotum 6 No O/T ++N, T ++C, T ++C, T & O - ++C, T & O
R- abdomen +C, O -O
11 8 m XY PGD M 46, XY with mosaicism
for 45, X/46, XY in
40 % of cells
L- abdomen
R- scrotum
6.5 No O/T - - ++C ++C +C
12 9 y XY PGD M 46, XY/47, XXY/45,X Abdomen 8 No O/T - - ++C - -T
+C, O
13 14 m XX PGD M 46, XX L- inguinal 8.5 No O/T ++N ++C ++C - ++C
R- scrotum
14a 12 m XY PGD M 45, X/46, XY R abdomen 8 No O/T ++N ++C ++C - ++C
14b 33 m XY PGD M 45, X/46, XY L-scrotal 8 No Dysgenetic Testis +N - ++C - +C
15 15 y XY PGD F 46, XY and gain
of chrom 16p11.2
Inguinal 2 No Dysgenetic Testis - - +C - -
16 2 m XY PGD F 45, X/46, XY Abdomen 4 No Dysgenetic Testis ++N ++C ++C - ++C
17 22 m XY PGD F 45, X/46, XY Inguinal 5 No Dysgenetic Testis ++N ++C ++C - +C
18 4 y XY PGD F 46, XY with gain
of chrom 2q14.1













Table 1 Clinical characteristics and immunohistochemical staining results (Continued)







Malignancy Gonadal tissue type OCT 3/4 PLAP Β-Catenin AFP CD117
19 16 y XY PGD F 46, XY Inguinal 5 No Dysgenetic Testis +C - ++C - +C
20 11 m XY PGD M 46, XY Inguinal 6 No Dysgenetic Testis - - - - -
21 6 m XY PGD M 46, XY L-scrotum 9 No Dysgenetic Testis ++N ++C ++C - ++C
R- abdomen
22 20 m XY PGD M 45, X/46, XY Inguinal 9 No Dysgenetic Testis - - ++C - -
23 7 m XY PGD F 46, XY,
t(11;16)(q22.1;q12.2)
Abdomen 1 GB-like GB-like arising from
immature testicular tissue
++N ++C ++C - ++C
24 11 m XY PGD M 46, XY L- abdomen 9.5 L gonad- GB GB arising from streak-like
ovarian tissue
++N ++C ++C - ++C
R- scrotum
25 17 y XY CGD F 46, XY Abdomen 1 GB with DG DG and GB arising from steak
gonad with Ovarian stroma
++N ++C ++C - ++C
26 18 y XY CGD F 46, XY Abdomen 1 R ovary- GB & DG GB and DG arising from streak
gonad with Ovarian stroma
++N ++C ++C - ++C
L ovary- GB
PGD Partial Gonadal Dysgenesis, CGD Complete Gonadal Dysgenesis, O/T Ovarian and Testicular Components, DG Dysgerminoma, GB Gondadoblastoma, - negative staining, + weakly positive, ++ strongly positive,













Fig. 1 Gonadoblastoma arising within Gonadal Dysgenesis: a Gonadoblastoma with large germ cells with vesicular nuclei, prominent nucleoli
and abundant cytoplasm and hyaline globules infiltrating adjacent gonad (H&E stain); b Nuclear immunoreactivity with OCT3/4; c CD117 (c-Kit)
cytoplasmic immunoreactivity; d Placental alkaline phosphatase (PLAP) cytoplasmic immunoreactivity
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71.9 %).
With respect to gonadal location, all samples with germ
cell neoplasia originated from abdominal gonads. Three of
the four patients with germ cell neoplasia were phenotypic
females with an EMS score of 1 (Patient 23 had clitorome-
galy and a single introitus which is not accounted for using
the EMS scoring system as there is no additional score forFig. 2 Dysgerminoma arising within Gonadal Dysgenesis: a Dysgerminoma
cytoplasm and with lymphocytes in background (H&E stain); b Nuclear immu
d Placental alkaline phosphatase (PLAP) cytoplasmic immunoreactivityclitoromegaly alone), whereas one patient with XY PGD
was phenotypically male and had an EMS score of 9.5.
Literature review: evidence and recommendations
In patients with GD, is there a predictive role of
immunohistochemical markers in the detection of germ
cell malignancy?with sheets of round large uniform tumor cells with granular
noreactivity with OCT3/4; c CD117 (c-Kit) cytoplasmic immunoreactivity;
Fig. 3 In Situ gonadoblastoma arising within Gonadal Dysgenesis: a Several noninvasive gonadoblastoma-like nests comprised of large germ cells
with vesicular nuclei, prominent nucleoli, and abundant cytoplasm and hyaline globules (H&E stain); b Nuclear immunoreactivity with OCT3/4;
c CD117 (c-Kit) cytoplasmic immunoreactivity; d Placental alkaline phosphatase (PLAP) cytoplasmic immunoreactivity
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Seven observational studies published between 2001 and
2013 were identified that assisted in answering this ques-
tion [10, 17–22]. The GRADE tool was used to evaluate
the evidence and provide recommendations. These stud-
ies are summarized in Table 3.
Among all the immunohistochemical markers evalu-
ated, OCT 3/4 had the most consistent staining intensity
for GB and DG, with PLAP and CD 117 showing less
consistent expression. Several studies have shown ex-
pression of OCT 3/4, PLAP, and CD 117 in undifferenti-
ated gonadal tissue adjacent to GB nests. Multiple
studies have suggested that OCT 3/4 -positive immature
germ cells in dysgenetic testes or undifferentiated gonadal
tissue are at high risk for development of GB [19–21].
The location of OCT 3/4-positive cells has been shown
to be important in differentiating between an in-situ neo-
plasia and maturation delay. In one study, all children
younger than 9 months old had OCT 3/4-positive cellsTable 2 Sensitivity, specificity, and positive predictive value for tumo
Tumor markers Sensitivity (95 % CI)
OCT 3/4, PLAP, and CD117 combined 100 % (40.2-100 %)
OCT 3/4 100 % (40.2-100 %)
PLAP 100 % (40.2-100 %)
Β-catenin 100 % (40.2-100 %)
CD117 100 % (40.2-100 %)
AFP 0 % (0-59.8 %)
Calculations based on the total case number of 26that were found centrally in the seminiferous tubules,
whereas in three older patients with CIS, OCT 3/4-positive
cells were located along the basal lamina [20]. The pres-
ence of OCT 3/4-positive cells in testicular parenchyma of
patients who are younger than 1 year of age is thought to
be due to germ cell maturation delay and, thus, cannot be
used to diagnose CIS [11].
Recommendations
1. In patients who are older than 1 year of age, the
presence of OCT 3/4-positive immature germ cells
located along the basal lamina in dysgenetic testes or
undifferentiated gonadal tissue confers a high risk
for development of germ cell neoplasia and should
lead to gonadectomy.
Evidence Quality: Low
Strength of Recommendation: Strongr markers (n = 26)
Specificity (95 % CI) Positive predictive value given prevalence
of gonadal malignancy as 15-40 %
73.9 (51.6-89.7 %) 40.3-71.9 %
52.2 % (30.6-73.1 %) 26.9-58.2 %
73.9 % (51.6-89.7 %) 40.3-71.9 %
4.4 % (0.7-22.0 %) 15.6-41.1 %
34.8 % (16.4-57.3 %) 21.3-50.6 %
95.7 % (78.0-99.3 %) 0 %
Table 3 GRADE evaluation of literature for immunohistochemical markers that can be used to determine high risk of malignancy in GD
Quality assessment Summary of findings Quality
Author Study design and objective Design limitations Sample Results/Conclusions
Inconsistency of results
Indirectness of evidence
Palma (2013) Retrospective Observational Study Insufficient sample size 18 gonadal samples from
15 pediatric patients with
45,X/46,XY PGD
1 patient had GB, 1 patient had DG Low
To determine whether OCT 3/4 and
β-Catenin are expressed in dysgenetic
gonads before GB development and
whether TSPY participates in malignant
invasive behavior
No inconsistencies Ages not specified 14/18 samples stained + for OCT 3/4
Head-to-Head comparison
in correct population
Only 3 samples stained + for β-catenin
-Seen in Dysgenetic testes, UGT, GB, and DG, not + in
streak tissue or mature germ cells
Tissue expressing OCT 3/4 and TSPY is associated with
a high risk for GB development.
Suggest that β-catenin is not involved in dysgenetic
gonad progression to GB, participates after GB is
established.
Barros (2011) Retrospective Observational Study Insufficient sample size 32 gonadal samples from
16 patients with Turner
Syndrome and Y chromosome
material
19 % had + nuclear OCT4 staining, suggesting the
presence of germ cell tumor cells (likely GB or CIS)
Low
To investigate the frequency of gonadal
tumors among patients with Turner
syndrome and Y-chromosome material
No inconsistencies Ages 8–18 yrs. OCT4 immunohistochemistry is more sensitive than
conventional H&E staining to indicate the risk of
development of germ cell tumors in TS patientsHead-to-Head comparison
in correct population
Palma (2008) Retrospective Observational Study Insufficient sample size 7 patients with PGD and GB OCT 3/4 was + in the nuclei of immature germ cells in GB Low
To evaluate the participation of β-catenin
and OCT 3/4 in the oncogenic pathways
involved in the transformation of GB
into seminoma/DG
No inconsistencies Ages 2–33 m Β-catenin was overexpressed in immature germ cells in GB
Head-to-Head comparison
in correct population
Β-catenin and OCT 3/4 co-localized in immature germ
cells in GB nests in all cases
The proliferation of immature germ cells in GB may be
due to an interaction between OCT 3/4 and accumulated
β-Catenin in the nuclei of the immature germ cells
Cools (2006) Retrospective Observational Study Insufficient sample size 60 gonadal samples from
43 patients with GD
Incidence of GCTs was 35 % Low
To define the histological origin of GB,
allowing the identification of high-risk
patients




In UGT found adjacent to GB, OCT 3/4, PLAP, and
c-KIT + germ cells were found
A gonadal biopsy revealing the presence of UGT with
OCT 3/4 + cells on the basal lamina contains high risk













Table 3 GRADE evaluation of literature for immunohistochemical markers that can be used to determine high risk of malignancy in GD (Continued)
Quality assessment Summary of findings Quality
Author Study design and objective Design limitations Sample Results/Conclusions
Inconsistency of Results
Indirectness of Evidence
Cools (2005) Retrospective Observational Study Insufficient sample size 58 gonadal samples from
30 patients with undervirilization
syndromes
OCT 3/4 was found in all patients <9 m of age Low
To distinguish germ cells with maturation




Ages 1 m-23 yrs. -In young patients and controls, OCT 3/4 + cells were
found centrally in the tubule
-In 3 older patients with CIS, OCT 3/4 + cells were found
along the basal lamina
Expression of PLAP and c-KIT was similar to OCT 3/4,
but less consistent
The presence of germ cells + for OCT 3/4, PLAP, or c-KIT
in patients < 1 yr is in accordance with expected maturation
delay and is insufficient for the diagnosis of CIS.
The location of OCT 3/4 positive cells is important in
differentiating between CIS and maturation delay
Kersemaekers (2005) Retrospective Observational Study Insufficient sample size 6 gonads from 5 patients
with GD containing GB
4 patients had DG arising from GB Low
To investigate the pathogenesis of GB




Ages 14–21 yrs. c-KIT was the least consistent marker
PLAP was + in all GBs and adjacent invasive components.
Most of the tumor cells in invasive DG were weakly +
or - for PLAP.
OCT 3/4 was + in all GBs and DGs
Seen in more immature cells, not mature cells
The development of an invasive germ cell tumor seems to
involve selection and clonal expansion of an immature
germ cell + for OCT 3/4 and TSPY
Slowikowska-Hilczer
(2001)
Retrospective Observational Study Insufficient sample size 23 patients with XY GD On the basis of PLAP expression, CIS was detected in
10 cases (43.5 %) with GD.
Low
Ages 3 m-7 yrs. GB was found in 4 cases of GD and DG was found in
1 patient with GD (17 years old)
No inconsistenciesTo investigate the appearance of CIS in
patients with 46,XY testicular dysgenesis
in different ages and in adult patients
from other groups
Head-to-Head comparison
in correct population Results showed a high prevalence of CIS in XY GD,
indicating the importance of early histopathological
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caution should be taken in interpreting positive
OCT 3/4 cells, as this finding can be reflective of
normal delay of germ cell maturation.
Evidence Quality: Low
Strength of Recommendation: Weak
Discussion
We studied 27 gonadectomy and gonadal biopsy samples
in 26 patients with GD to investigate pre-malignant and
malignant characteristics and identify factors that might
be useful in predicting the development of germ cell ma-
lignancy and, thus, guide the decision-making process
for performing a gonadectomy. Our findings as com-
pared to what has been reported in the literature are
summarized in Table 4.
The overall prevalence of GCTs found in the 26 pa-
tients with GD included in this series was 11.5 % (n = 3),
with an additional patient having evidence of in-situ GB-
like tissue. Invasive GCTs were found in 7.7 % (n = 2).
Excluding the four patients with XX GD, the prevalence
of GCTs becomes 13.6 %, which is slightly lower than
the prevalence of 15-40 % seen in patients with XY GD
as reported in previous studies. An important limitation
in interpreting the prevalence of GCT in our study
compared to previous studies is our small sample size.
All patients in our series with a GCT had abdominal
gonads, consistent with previous studies reporting the
highest risk of malignancy in abdominal gonads and the
lowest risk in scrotal gonads. The age of the patients in
our study with in-situ or invasive germ cell neoplasia
ranged from 7 months to 18 years, with the two older
patients (ages 17 and 18 years) having invasive germ cell
neoplasia. GB has been described in patients with XY
GD younger than 1 year of age [23, 24].Table 4 Comparison of features between the present study and pre
Present study
Prevalence of germ cell tumor in GD population 11.5 %
Age 7 m - 18 y
Location of gonads in patients with malignancy 100 % in abdomen
Degree of virilization in patients with malignancy 3 of 4 pts were pheno
1 pt was ambiguous.
Gross pathology findings 3 pts had GB arising f
with ovarian stroma.
1 pt had GB arising fro
testicular tissue.
Immunohistochemistry All pts with GCT had
of OCT 3/4, PLAP, β-caOCT 3/4, CD117, and PLAP are established markers
of germ cell malignancy, and these three markers were
easily identified in all patients in our series with either
in-situ or invasive GCTs. Whereas all the immunohisto-
chemical markers besides AFP provided high sensitivity
for GCTs, PLAP showed the highest specificity in our
study. β-Catenin was identified in 96 % of the samples
and, thus, was the least specific for germ cell neoplasia.
Consistent with what has been seen in other studies,
OCT 3/4 showed robust, nuclear staining and was easily
identifiable [25]. Our data suggest that in patients with
GD who are older than 1 year of age, the simultaneous
expression of OCT 3/4, PLAP, and CD117 should be an
indication for performing gonadectomy, as these markers
are highly sensitive for germ cell malignancy and pre-
invasive lesions. In patients reared as males with mild
undervirilization and gonads that can be repositioned sur-
gically into the scrotum, gonadal biopsy with staining for
these markers should be considered at the time of orchi-
dopexy to evaluate the malignant potential.
Although OCT 3/4, CD117, and PLAP are highly
sensitive, their low specificity renders their use in clinical
practice difficult in ruling out germ cell malignancy,
particularly when evaluating patients who are younger
than 1 year of age. A study looking at these markers in
normal fetal testicular development showed that OCT
3/4, CD 117, and PLAP can be present in the germ cells
of neonates as germ cell maturation delay or block is ex-
pected, and they are unreliable in detecting CIS/ITGCNU
in very young children [11]. As seen in our study, two
patients younger than 1 year of age had evidence of GB
(age, 11 months) or in-situ GB-like tissue (age, 7 months);
hence, further criteria are needed to identify patients at
risk for malignancy in this age group. In these younger pa-
tients, surrogate measures including location of gonads,
morphology of gonadal tissue, function of testicular tissuevious studies
Previous studies
15-40 %
Wide age range at presentation. GB has been
identified in cases < 1 yr of age.
Abdominal gonads have been shown to have
highest risk of malignant transformation.
typic female. Low risk: Normally virilized males
Intermediate Risk: Mild undervirilization
High Risk: Ambiguous genitalia
rom streak gonad Low Risk: Streak gonad without germ cells, ovary,
testis without immature germ cells




OCT 3/4, PLAP, β-catenin, and CD117 are
established markers of germ cell malignancy.
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tion should be evaluated to determine risk for developing
malignant transformation. Future outcomes studies are
needed to determine the usefulness of these additional
measures in determining the potential for development of
a malignancy.Conclusions
We analyzed our data and used a systematic method to
evaluate the literature to provide recommendations for
the usefulness of immunohistochemical markers in de-
tecting premalignant and malignant germ cell tumors in
gonadal dysgenesis. Our findings are consistent with the
literature with regards to the usefulness of OCT 3/4 as a
marker that is highly reliable for germ cell malignancy
and pre-invasive lesions in patients older than 1 year of
age. Our data also demonstrate the usefulness of PLAP
and CD117 in addition to OCT 3/4 in assessing pre-
malignant potential. Additional criteria seen in both our
study and the literature including abdominal gonads and
undervirilization are important risk factors for germ cell
malignancy in patients with XY gonadal dysgenesis. It is
critical to identify each patient’s individual risk for ma-
lignancy and careful consideration is required before go-
nadal biopsy and/or gonadectomy are recommended. As
seen in our study, patients younger than 1 year of age
can present with germ cell malignancy, however, the use
of immunohistochemical markers is not reliable in asses-
sing premalignancy in this age group. Thus, to prevent
unnecessary gonadectomy in these younger patients, fur-
ther studies are needed to evaluate surrogate measures
that can be used to predict risk of malignancy. In sum-
mary, we have set the stage for evaluation of malignancy
risk and the decision-making process for gonadectomy
in patients with GD using immunohistochemistry; an
approach confirmed by our literature review. We have
indicated that surrogate measures need to be elaborated
to determine which patients require gonadal biopsy and/
or gonadectomy. This paper offers a preliminary over-
view of the available evidence and what risk factors need
to be assessed in anticipation of gonadectomy. A more
standardized approach is needed for the management of
these patients.
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